iPS cell-derived inner ear cells may improve congenital hearing loss

9 February 2018

By efficiently differentiating inner ear cells from human iPS cells, it was possible to produce a large number of target cells and a large number of protein expressions unique to inner ear cells other than CONNEXIN. Furthermore, transplantation into the inner ears of embryonic mice was successful. Credit: Dr. Hiroki Takeda

A Japanese research group has successfully grafted human iPS cell-derived inner ear cells that express human-derived proteins into the inner ears of embryonic mice. Hereditary hearing loss accounts for about half of all congenital hearing loss cases, and this work is a major contribution toward research that targets the embryonic inner ear.

With an incidence frequency of one per 500 to 1,000 newborns, congenital hearing loss is the most frequently occurring congenital disease, and approximately half of all congenital hearing loss cases are hereditary. Treatment for this kind of hearing loss includes cochlear implants and hearing aids, but there is no fundamental therapy.

In human hereditary hearing loss, deafness has already occurred during fetal development, so treatment during this stage would be most effective. The GJB6 gene encodes the Connexin 30 protein, which is essential in hearing development, and a deficiency of the gene results in the second-most common disease among cases of hereditary hearing loss that have no other disease in the inner ear.

In previous work, Dr. Ryosei Minoda, head of the Department of Otolaryngology at Kumamoto General Hospital, reported that hearing loss was restored by gene therapy to the inner ear of Connexin 30-deficient fetal mice. The current research team, which includes Dr. Minoda and Dr. Hiroki Takeda of Kumamoto University and several researchers from Keio University, has successfully grafted human iPS-derived cells into the inner ears of embryonic mice, a feat with a high level of technical difficulty.

Gene knockout mice lacking the CONNEXIN 30 protein experience hearing loss due to sensory cells dysfunction as the ion potential of the sensory cells inside the inner ear decreases after birth. In this study, human iPS cell-derived cells were transplanted into Connexin 30 knockout mice during the embryonic stage. The transplanted cells were engrafted in the treated inner ear and some cells began expressing CONNEXIN 30 after seven days had passed. Credit: Dr. Hiroki Takeda
First, the research team succeeded in efficiently inducing inner ear cells expressing inner ear specific proteins, such as Connexin 26, Connexin 30, and Pendrin, from human iPS cells. They transplanted progenitors of the inner ear cells into the inner ears of embryonic normal and Connexin 30 knockout mice using glass tubes with optimized tip sizes. The transplanted cells grafted to various sites throughout the inner ear in both groups. However, the Connexin 30 knockout mice had more grafted cells than the normal mice, and some of the grafted cells were found to express Connexin 30.

The fact that Connexin 30 knockout mice had a higher number of grafted cells than normal mice, and that some of the grafted cells expressed Connexin 30 is a very important finding when considering cell transplantation as a treatment for hereditary hearing loss caused by Connexin deficiency. Cell transplantation can compensate for missing Connexin and may improve hearing loss by adding properly functioning Connexin proteins. Future work will attempt to increase the number of grafted cells and improve hearing ability. The prevention of hearing loss is an exciting prospect.

Furthermore, this study revealed that cells derived from humans can be grafted into the heterozygous inner ear of mouse embryos. This adds the possibility of in vivo experiments on therapeutic effects using human-derived cells in the mouse embryo. It is thought that this line of research can greatly contribute to the development of a fundamental treatment for hereditary hearing loss and inner ear development research.


Provided by Kumamoto University